Story
Schott Pharma Lifts Full-Year Guidance on Syringe Demand Rebound

Schott Pharma has raised its financial outlook for the 2026 fiscal year, pointing to a recovery in demand for polymer syringes and continued strong sales of glass syringes for popular GLP-1 weight-loss and diabetes drugs. The company confirmed the upgraded forecast on Wednesday alongside its third-quarter results.
Upgraded Outlook
Schott Pharma now expects full-year revenue growth of 5% to 6% on a constant exchange rate basis, an increase from its previous forecast of 2% to 5%. The company also lifted its adjusted EBITDA margin guidance to a range of 27% to 28%, up from approximately 27% previously.
The improved forecast is underpinned by a rebound in its polymer syringe business and robust, ongoing demand for high-value glass syringes, which are critical components for injectable GLP-1 therapies. The company also noted it had reached an agreement with an undisclosed major glass syringe customer that includes revenue-generating elements and compensation payments.
Third-Quarter Performance
For the third quarter, Schott Pharma reported revenue of €282 million, a 10% increase year-over-year, or 8.3% at constant exchange rates. However, profitability was pressured during the period.
Ad- EBITDA: €76 million
- EBITDA Margin: 26.8%, a decline from 32.3% in the same quarter last year.
This margin contraction was primarily attributed to lower capacity utilization for polymer syringes and costs associated with production optimization within its Drug Delivery Systems segment.
Segment Highlights
The company's performance varied across its two main divisions. The Drug Containment Solutions segment, which includes glass vials and syringes, saw revenue grow 11.3% year-over-year to €159 million, with an EBITDA margin of 23.8%.
In contrast, the Drug Delivery Systems segment posted revenue of €123 million, an 8.6% increase. However, its EBITDA margin fell significantly to 29.4% from 36.9% in the prior-year quarter, reflecting the aforementioned production challenges.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.